Apogee Therapeutics
NASDAQ · APGE·Waltham, MA·Mid-cap·Phase 3
Clinical-stage biotech developing half-life extended monoclonal antibodies for I&I diseases. Lead program zumilokibart (APG777) is an anti-IL-13 antibody advancing to Phase 3 in atopic dermatitis, with additional programs in asthma, COPD, and EoE.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Apogee Therapeutics Corporate Presentation | Corporate overview | March 29, 2026 | 26 |